FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPROVAL										
l	OMB Number:	3235-0287									
l	Estimated average burden										
l	hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar Olinge		2. Issuer Name and Ticker or Trading Symbol Amylyx Pharmaceuticals, Inc. [AMLX]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify									
(Last)	,	irst)		3. Date of Earliest Transaction (Month/Day/Year) 07/12/2023									below)		nercia	below)	pecify			
43 THO	RNDIKE S	TREET	4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)								
(Street) CAMBRIDGE MA 02141															X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Tab	le I - No	n-Deriv					quired, [i				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da						Execution D			Code (Instr.					, 4 and Secu Ben Own		ally following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) o (D)	r Price	T	Reported Transaction(s) (Instr. 3 and 4)					
Common	2/2023	′2023		M		20,00	0 A	\$0.3	251,1		,108		D							
		Т							uired, Di , option:					y Ow	ned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	ode V		(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares	er						
Stock Option (Right to	\$0.37	07/12/2023			M			20,000	(1)	05	5/13/2029	Common Stock	20,000	\$(0.00	69,577	7	D		

Explanation of Responses:

1. As of the date of this filing, 67,156 shares subject to the option are vested and exercisable. 2,421 shares subject to such option vest and become exercisable in substantially equal monthly installments until August 13, 2023.

/s/ Joshua B. Cohen, as Attorney in Fact

07/14/2023

rectly

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.